Other languages Inovio Pharmaceuticals, Inc.

Equities

INO

US45773H4092

Market Closed - Nasdaq Other stock markets 01:30:00 18/06/2024 am IST			5-day change	1st Jan Change
8.94 ^USD	-1.65%		-8.02%	+46.08%

14/05	Stephens Starts Inovio Pharmaceuticals With Overweight Rating, $20 Price Target	MT
13/05	Transcript : Inovio Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 13, 2024

Other languages

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Inovio Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	14/05
Inovio Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	07/03
Inovio Pharmaceuticals, Coherus BioSciences to Collaborate on Potential Throat Cancer Treatment	04/01
INOVIO and Coherus Announces Clinical Collaboration to Advance Development of INO-3112 in Combination with LOQTORZI?? (toripalimab-Ttzi)	04/01
Inovio Pharmaceuticals Plans BLA Submission for INO-3107 for Recurrent Respiratory Papillomatosis Treatment	04/01
INOVIO Plans to Submit a BLA for INO-3107 as a Potential Treatment for RRP in Second Half of 2024 Under Accelerated Approval Program	03/01
Inovio Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	10/11
Inovio Pharmaceuticals Advised to File BLA for Drug Candidate to Treat Recurrent Respiratory Papillomatosis	10/23/10
Inovio Pharmaceuticals, Inc. Receives FDA Feedback That Data from Completed Phase 1/2 Trial of INO-3107	10/23/10
Inovio Says US FDA Breakthrough Therapy Designation Received for Recurrent Respiratory Papillomatosis Drug Candidate	07/23/07
Inovio Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	10/23/10
Inovio Pharmaceuticals to Cut 30% of Full-Time Workforce	01/23/01
Inovio Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	11/23/11
Inovio Pharmaceuticals Says Trial Data Shows INO-3107 for Papillomatosis Is Well Tolerated, Reduces Surgery	08/23/08
INOVIO Presents New Data from A Phase 1/2 Trial of INO-3107 for the Treatment of Recurrent Respiratory Papillomatosis	08/23/08
Inovio Pharma Says EMA Panel Backed Approval of Orphan Designation for Respiratory Disease Drug Candidate	26/23/26
European Committee for Orphan Medicinal Products Provides Positive Opinion on Inovio's Application for Orphan Drug Designation for INO-3107	26/23/26
Inovio Pharmaceuticals, Inc. Announces Data from Phase 1b Trial with INO-4201 as an Ebola Booster for rVSV-ZEBOV (Ervebo®) Presented at ECCMID 2023	17/23/17
Inovio Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	02/23/02
Inovio Pharma Reports Positive Preliminary Results in Recurrent Respiratory Papillomatosis Trial	17/23/17

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Inovio Pharmaceuticals, Inc.

Equities

INO

US45773H4092

Other languages

Filters